LillyDirect
Direct from Lilly
Eli Lilly's direct-to-consumer platform providing streamlined access to Zepbound (tirzepatide) and the new Foundayo (orforglipron) GLP-1 pill at reduced cash-pay prices.
Medications Available
Pros
- FDA-approved medications directly from manufacturer
- NEW Foundayo (orforglipron) oral GLP-1 pill — no food/water restrictions
- Significant discount vs retail pricing (up to 70% off)
- No purity or quality concerns (authentic Lilly product)
- KwikPen multi-dose pen option (launched Feb 23, 2026)
- Home delivery with cold chain handling
- Available through multiple telehealth partners
- Walmart retail pickup available
- HSA/FSA eligible
- Medicare Zepbound KwikPen coverage at $50/mo copay LIVE since April 1, 2026
- Foundayo Medicare coverage expected July 2026 at $50/mo
Cons
- Requires separate prescription from provider
- Higher cost than compounded alternatives
- Only Lilly products available — no semaglutide
- Must refill within 45 days or pay standard higher prices
- With commercial insurance coverage, copay can be as low as $25/mo
Compare LillyDirect With
See how LillyDirect stacks up against other providers
How LillyDirect Ranks
See where LillyDirect places in our expert rankings
About LillyDirect
LillyDirect is Eli Lilly’s direct-to-consumer platform launched in 2024, providing streamlined access to Lilly’s GLP-1 portfolio at significantly reduced cash-pay prices. As of April 2026, the platform offers Zepbound (tirzepatide injection vials and the KwikPen multi-dose pen) plus the newly approved Foundayo (orforglipron) — the only GLP-1 pill that can be taken any time of day with no food or water restrictions. Medications ship directly to patients’ homes (Foundayo also ships via Amazon Pharmacy and Prescryptive).
How It Works
- Get a Prescription - Obtain a valid Zepbound prescription from your provider or telehealth partner
- Order Through LillyDirect - Access reduced self-pay pricing at lillydirect.com
- Home Delivery - Medication ships with cold chain handling, or pickup at Walmart
- Refill Regularly - Must refill within 45 days to maintain discounted pricing
Telehealth Partners
LillyDirect works with multiple telehealth providers for prescriptions:
- Ro
- LifeMD
- Teladoc Health
- Noom (via Gifthealth)
- Form Health
- knownwell
- WeightWatchers Clinic
Pricing (May 2026)
Zepbound (Tirzepatide)
| Format | Dose | Price |
|---|---|---|
| Vial or KwikPen | Zepbound 2.5mg | $299/mo |
| Vial or KwikPen | Zepbound 5mg | $399/mo |
| Vial or KwikPen | Zepbound 7.5mg | $449/mo |
| Vial or KwikPen | Zepbound 10mg | $449/mo |
| Vial or KwikPen | Zepbound 12.5mg | $449/mo |
| Vial or KwikPen | Zepbound 15mg | $449/mo |
Foundayo (Orforglipron) — NEW
| Dose | Self-Pay Price |
|---|---|
| 0.8 mg (starter) | $149/mo |
| 2.5 mg | $199/mo |
| 5.5 – 9 mg | $299/mo |
| 14.5 – 17.2 mg | $299/mo (continuous) or $349/mo (gaps >45 days) |
Foundayo was approved April 1, 2026 and began shipping through LillyDirect on April 6. The Foundayo Savings Card brings cost as low as $25/month for commercially insured patients.
Important (Zepbound): If you miss the 45-day refill window for doses 7.5mg and above, standard self-pay prices apply: 7.5mg: $599, 10mg: $699, 12.5mg: $849, 15mg: $1,049. You can re-enroll in the Self Pay Journey Program with your next order.
With Insurance: If you have commercial drug insurance with Zepbound or Foundayo coverage, you may pay as low as $25 for a 1- or 3-month supply.
Medicare Coverage:
- Zepbound KwikPen Medicare coverage at $50/mo copay went live April 1, 2026
- Foundayo Medicare coverage at $50/mo copay expected to begin July 1, 2026 via the Medicare GLP-1 Bridge program (extended through 2027 per CMS’s April 21, 2026 update)
Recent News (May 2026)
- Foundayo (orforglipron) FDA Approved (April 1, 2026): Lilly’s oral GLP-1 pill — no food or water restrictions — now shipping via LillyDirect, Amazon Pharmacy, and Prescryptive
- LifeMD partnership: LifeMD began offering Foundayo via LillyDirect integration April 10, 2026 (other telehealth partners adding access throughout May)
- Medicare Zepbound Live: $50/mo Part D copay went into effect April 1, 2026 for the Zepbound KwikPen
- TrumpRx Integration: Zepbound available through TrumpRx.gov at ~$350/mo for uninsured patients
- KwikPen: Multi-dose pen format (launched Feb 23, 2026) continues at vial pricing
Who Is This Best For?
- Patients who want authentic FDA-approved tirzepatide or orforglipron
- Those who want a no-restriction oral GLP-1 (Foundayo)
- Patients concerned about compounded medication quality
- People who already have a prescription from their provider
- Patients seeking significant savings vs retail Zepbound pricing ($1,000+/mo)
- Medicare beneficiaries (Zepbound KwikPen at $50/mo live now; Foundayo coming July 2026)
- Those who prefer to pay with HSA/FSA funds
The Bottom Line
LillyDirect is now the most complete manufacturer-direct GLP-1 storefront on the market, offering both injectable Zepbound (from $299/mo) and the new Foundayo oral pill (from $149/mo). The KwikPen format adds convenience, Medicare Zepbound coverage at $50/mo is live, and Foundayo Medicare coverage is expected July 1. For patients prioritizing authentic FDA-approved medications with predictable pricing, LillyDirect is the clear default.
Last updated: May 2026
Last verified: May 2026
Ready to try LillyDirect?
Compare with other providers or visit their website to get started.